Bristol-Myers Squibb ( (BMY) ) has shared an update.
On February 6, 2025, Bristol-Myers Squibb announced its financial results for the fourth quarter and full year of 2024, highlighting a revenue increase to $12.3 billion for the fourth quarter, driven by its Growth Portfolio and increased demand for Eliquis. The company also reported achieving significant clinical and regulatory milestones, including the U.S. approval of Opdivo Qvantig and the launch of Cobenfy for schizophrenia treatment, positioning these developments as new growth drivers. The company aims for additional cost savings through its strategic productivity initiative, projecting $2 billion in savings by 2027.
More about Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines for patients with serious diseases. It specializes in oncology, immunology, cardiovascular, and fibrotic therapeutic areas.
YTD Price Performance: 6.74%
Average Trading Volume: 10,972,110
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $121.1B
For an in-depth examination of BMY stock, go to TipRanks’ Stock Analysis page.